Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
33.48 USD | -4.33% |
|
+37.73% | 0.00% |
06-28 | Biopharma firm Alumis' shares fall nearly 16% in Nasdaq debut | RE |
06-27 | SoftBank Group to Form Joint Venture with Tempus AI | CI |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Net sales 1 | 62.06 | 188 | 257.9 | 320.7 | 531.8 |
EBITDA 1 | -104.8 | -163.5 | -214.6 | -238.7 | -155.8 |
EBIT 1 | -119.8 | -186.6 | -238.5 | -269.1 | -189.1 |
Operating Margin | -193.02% | -99.23% | -92.49% | -83.93% | -35.56% |
Earnings before Tax (EBT) 1 | -115 | -209.9 | -259.2 | -289.7 | -213.8 |
Net income 1 | -115 | -209.9 | -259.2 | -289.8 | -214.1 |
Net margin | -185.23% | -111.62% | -100.52% | -90.38% | -40.26% |
EPS | - | -4.033 | -4.728 | -5.298 | -4.201 |
Free Cash Flow | - | -140 | -122.1 | -120.7 | -105.9 |
FCF margin | - | -74.46% | -47.37% | -37.63% | -19.91% |
FCF Conversion (EBITDA) | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - |
Dividend per Share | - | - | - | - | - |
Announcement Date | 01/09/21 | 01/09/21 | 27/04/22 | 25/08/23 | 20/05/24 |
Balance Sheet Analysis
Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|
Net Debt 1 | - | - | - | 130 | 291 |
Net Cash position 1 | 225 | 262 | 38.7 | - | - |
Leverage (Debt/EBITDA) | - | - | - | -0.5449 x | -1.865 x |
Free Cash Flow | - | -140 | -122 | -121 | -106 |
ROE (net income / shareholders' equity) | - | -66% | -119% | 4,797% | 113% |
ROA (Net income/ Total Assets) | - | -20.8% | -23.2% | -28.9% | -19.8% |
Assets 1 | - | 1,010 | 1,116 | 1,002 | 1,083 |
Book Value Per Share | - | -8.150 | -12.80 | -17.80 | -21.80 |
Cash Flow per Share | - | 8.150 | 4.410 | 4.790 | 2.610 |
Capex 1 | 17 | 13.4 | 11.8 | 18.4 | 34.6 |
Capex / Sales | 27.45% | 7.14% | 4.56% | 5.73% | 6.51% |
Announcement Date | 01/09/21 | 01/09/21 | 27/04/22 | 25/08/23 | 20/05/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
0.00% | 5.77B | |
+22.92% | 45.51B | |
-7.20% | 38.52B | |
+38.87% | 38.13B | |
+27.60% | 30.74B | |
-13.50% | 26.03B | |
+13.52% | 25.92B | |
+46.03% | 14.13B | |
+36.35% | 12.73B | |
-5.15% | 11.29B |
- Stock Market
- Equities
- TEM Stock
- Financials Tempus AI, Inc